PTK2 and pancreatic ductal adenocarcinoma: Reports from a phase I trial evaluating the safety of FAK inhibitor PF-04554878 when used in combination with pembrolizumab or gemcitabine in patients with pancreatic ductal adenocarcinoma demonstrated a targeted decrease in FAK phosphorylation in T cells; however, no partial or complete response was observed 166.